title: PD1/PD1L pathway, HLA-G and T regulatory cells as new markers of immunosuppression in cancers.
abstract: The appropriate function of the immune system depends on the effective regulation of the immune response on multiple levels. The key element of an effective immune response to antigenic stimulation is maintaining a homeostasis between activation and inhibitory function of immunocompetent cells and molecules. In pathological conditions such as chronic infections, autoimmune diseases or cancer there are significant alterations, and prevalence of signals of one type over another. Main markers of these dysfunctions are altered expressions of molecules, such as programmed death-1 (PD-1), Human Leukocyte Antigen G (HLA-G), or changed percentages of T regulatory cells (Treg). These indicators of immune system dysfunction may contribute to disease progression, but also could represent good targets for treatment. Interestingly, in recent years there are many new, interesting reports which showed that the role of PD-1, HLA-G or Treg is ambiguous and not always their higher expression or frequency lead to the progression of disease. Recent studies have shown that Treg can suppress bacteria-driven inflammation which promotes carcinogenesis and thus protect the host from cancer development. Moreover, proliferation of hematological tumor cells expressing ILT-2 receptor can be inhibited by HLA-G, in contrast to solid tumors where HLA-G favors tumor escape. In this paper we present characteristics of expressions of PD-1 and its ligands, HLA-G, and frequency of Treg cells in a variety of physiological and pathological conditions associated with chronic infections, autoimmune diseases and cancer. The understanding of the complex interactions between the functional elements of immune system is essential for a detailed characteristics of the mechanisms leading to the development of diseases and identification of more effective targeted therapies.
authors.affiliation: Zakład Hematoonkologii Doświadczalnej, Uniwersytet Medyczny w Lublinie.
authors.forename: Paulina
authors.initials: P
authors.lastname: Własiuk
authors.affiliation: Zakład Hematoonkologii Doświadczalnej, Uniwersytet Medyczny w Lublinie.
authors.forename: Maciej
authors.initials: M
authors.lastname: Putowski
authors.affiliation: Zakład Hematoonkologii Doświadczalnej, Uniwersytet Medyczny w Lublinie.
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Giannopoulos
mesh_terms: D000818:Animals; D001327:Autoimmune Diseases / Q000276:immunology; D015395:Histocompatibility Antigens Class I / Q000276:immunology*; D006801:Humans; D007165:Immunosuppression Therapy; D009369:Neoplasms / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D061026:Programmed Cell Death 1 Receptor / Q000276:immunology*; D015398:Signal Transduction; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*; D019139:Tumor Escape
chemical_list: D015395:Histocompatibility Antigens Class I; D061026:Programmed Cell Death 1 Receptor